GCM
GILD icon

Grisanti Capital Management’s Gilead Sciences GILD Stock Holding History

Grisanti Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-107,524
Closed -$8.71M – 76
2017
Q3 		$8.71M Buy
107,524
+105
+0.1% +$8.03K 3.58% 11
2017
Q2 		$7.6M Sell
107,419
-21,053
-16% -$1.4M 3.27% 13
2017
Q1 		$8.73M Buy
128,472
+36,074
+39% +$2.54M 3.66% 10
2016
Q4 		$6.62M Buy
+92,398
New +$6.87M 2.97% 16
2015
Q1 		– Sell
-1,500
Closed -$141K – 57
2014
Q4 		$141K Buy
+1,500
New +$155K 0.05% 49

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Grisanti Capital Management's GILD Position: Q4 2017 in Review

Grisanti Capital Management sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 107,524 shares — an estimated $8.71M sold.

Grisanti Capital Management first reported a position in GILD in Q4 2014 and held it in 5 quarters. The position peaked at $8.73M in Q1 2017. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

  • Grisanti Capital Management reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
  • Grisanti Capital Management sold 107,524 Gilead Sciences shares in Q4 2017, an estimated $8.71M.
  • Grisanti Capital Management first reported a position in Gilead Sciences in Q4 2014 and held it in 5 quarters.
  • Grisanti Capital Management's Gilead Sciences position peaked at $8.73M in Q1 2017.
  • 1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Grisanti Capital Management's 13F filing for Q4 2017, filed 7 Feb 2018.